Can Urate Lowering Therapy Be Stopped in Gout? Rationale and Design of Two Large Randomised Trials
Open Access
- 22 January 2025
- journal article
- research article
- Published by MDPI AG in Gout, Urate, and Crystal Deposition Disease
- Vol. 3 (1) , 2
Abstract
Lifelong urate-lowering therapy (ULT) is recommended for gout to prevent flares and urate deposition. However, concerns about its adherence, long-term side effects, and the necessity of continuous treatment after achieving remission raise critical questions. Two randomised controlled trials (RCTs), GO TEST Finale and STING, aim to evaluate the safety and feasibility of ULT discontinuation in gout patients in remission. The GO TEST Finale is a superiority trial involving 310 patients in the Netherlands, comparing a treat-to-target (T2T) ULT continuation strategy with ULT discontinuation. Patients in the discontinuation arm resume ULT only after flare recurrence or tophi development. The primary outcomes focus on remission criteria failure over 24 months, while the secondary outcomes explore predictors of successful discontinuation and cost-effectiveness. The STING study, a non-inferiority trial in France, includes 450 patients without ultrasound (US) evidence of urate deposits. Patients in the discontinuation group resume ULT if a US detects urate deposition during follow-up, minimising flare risk. The primary outcomes measure the proportion of patients experiencing flares at two years, with the secondary outcomes examining the long-term health impacts and cost-effectiveness. These trials provide an opportunity for translational research into the immunological and epigenetic effects of rising serum urate levels. The results could inform personalised strategies for a drug-free period and address the critical question of whether lifelong ULT is necessary for gout management. The complementary findings from both trials are expected to contribute significantly to resolving this ongoing clinical debate.Keywords
Funding Information
- ZonMw (80-87600-98-19030, 10330022010003, PHRC-N 22-0134)
- National Hospital Clinical Research Programme (80-87600-98-19030, 10330022010003, PHRC-N 22-0134)
This publication has 26 references indexed in Scilit:
- Trained immunity and inflammation in rheumatic diseasesJoint Bone Spine, 2022
- 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapyJoint Bone Spine, 2020
- Allopurinol hypersensitivity: Pathogenesis and preventionBest Practice & Research Clinical Rheumatology, 2020
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis & Rheumatology, 2020
- Prevalence and discrimination of OMERACT-defined elementary ultrasound lesions of gout in people with asymptomatic hyperuricaemia: A systematic review and meta-analysisSeminars in Arthritis and Rheumatism, 2019
- Effects of Discontinuation of Urate-Lowering Therapy: A Systematic ReviewJournal of General Internal Medicine, 2017
- Brief Report: Validation of a Definition of Flare in Patients With Established GoutArthritis & Rheumatology, 2017
- Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricemia: Comparison With Normouricemic IndividualsArthritis Care & Research, 2017
- Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus ExercisesArthritis Care & Research, 2015
- A two-stage approach to the treatment of hyperuricemia in gout: The “dirty dish” hypothesisArthritis & Rheumatism, 2011